-
Mashup Score: 0Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer - 7 month(s) ago
Long-term survival analyses of HER2-targeted therapies are lacking. This is a 20-year follow-up study of a phase II trial that evaluated the activity and safety
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 25
PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non–small-cell lung cancer (mNSCLC). METHODS DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate (ORR) per RECIST v1.1 by blinded independent central review. RESULTS One hundred fifty-two patients were randomly assigned 2:1 to T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. As of December 23, 2022, the median duration of follow-up was 11.5 months (range, 1.1-20.6) with 5.4 mg/kg an
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
🔥🚨@OncoAlert Hot off the press, just published @JCO_ASCO, simultaneously with presentation @IASLC #WCLC23, results of #DESTINY-Lung02, Phase II Trial of #Trastuzumab Deruxtecan (T-DXd) in Patients With #HER2-Mutant Metastatic #NSCLC. #LCSM 👇🏼 https://t.co/7sUA5USKWs https://t.co/TA9Clbai4g
-
-
Mashup Score: 0Trastuzumab Biosimilar Plus Paclitaxel Shows Promise for Patients With HER2-Positive Recurrent or Metastatic Urothelial Carcinoma - 8 month(s) ago
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Enhanced binding at fever temperatures of HER2 in complex with trastuzumab and pertuzumab | Immunotherapy - 10 month(s) ago
Aim: Fever follows the administration of trastuzumab and pertuzumab used in HER2-relevant immunotherapy, but is often eliminated in clinical practice. This work explores the role of temperature (37–39°C) in the formation of immune complexes between HER2 with either trastuzumab or pertuzumab or with both antibodies. Materials & methods: Using molecular dynamics simulations and free energy…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRC - 10 month(s) ago
Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Autoimmune hypothyroidism and trastuzumab therapy: a rare association - 11 month(s) ago
Summary We report a case of a woman with a diagnosis of breast cancer who unintentionally started gaining weight, feeling tired, and constipated 44 weeks after the initiation of trastuzumab. Hypothyroidism secondary to an autoimmune thyroiditis associated with trastuzumab was diagnosed, the first case described in Portugal and the fourth case described worldwide. Our intention regarding the…
Source: EDM Case ReportsCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
In the biomarker analysis of the phase 3 NeoALTTO study, a small reduction in antimüllerian hormone levels were seen during 2 weeks of anti-HER2 treatment alone followed by a significant decline in most patients with HER2-positive breast cancer after combining with weekly paclitaxel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 11
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and…
Source: oncbrothers.comCategories: Hem/Oncs, Latest HeadlinesTweet
This study provides the longest follow-up on #trastuzumab therapy in patients with HER2+ metastatic #breastcancer. Use of TCH regimen resulted in a 10% long-term OS (median OS = 39.78 months). #bcsm @breastoncdoc https://t.co/nMvwqqG8yM https://t.co/5COFCbGaEx